An RNAi-based Screen Reveals PLK1, CDK1 and NDC80 As Potential Therapeutic Targets in Malignant Pleural Mesothelioma
Overview
Authors
Affiliations
This corrects the article DOI: 10.1038/bjc.2017.85.
as a potential pan-cancer diagnostic, prognostic, and immunological biomarker.
Tao L, Xu X, Fang Z, Christopoulos P, Cortinovis D, Lu Y Transl Cancer Res. 2024; 13(3):1533-1553.
PMID: 38617518 PMC: 11009796. DOI: 10.21037/tcr-23-2016.
Development of an interfering peptide M1-20 with potent anti-cancer effects by targeting FOXM1.
Bu H, Lan X, Cheng H, Pei C, Ouyang M, Chen Y Cell Death Dis. 2023; 14(8):533.
PMID: 37598210 PMC: 10439915. DOI: 10.1038/s41419-023-06056-9.
shRNA targeting PLK1 inhibits the proliferation and invasion of nasopharyngeal carcinoma cells.
Zhou Y, Wu C, Liu B, Zhu J, Zhong Y, Yuan Y Transl Cancer Res. 2022; 9(9):5350-5359.
PMID: 35117900 PMC: 8798612. DOI: 10.21037/tcr-20-811.
Qin S, Yang Y, Zhang H, Zheng X, Li H, Wen J Transl Cancer Res. 2022; 10(1):469-478.
PMID: 35116276 PMC: 8797450. DOI: 10.21037/tcr-20-2945.
Wijnen R, Pecoraro C, Carbone D, Fiuji H, Avan A, Peters G Cancers (Basel). 2021; 13(17).
PMID: 34503199 PMC: 8430873. DOI: 10.3390/cancers13174389.